Janus Henderson Group
GPCR icon

Janus Henderson Group’s Structure Therapeutics GPCR Stock Holding History

Janus Henderson Group’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$258M Buy
5,354,981
+264,833
+5% +$18.1M 0.12% 163
2025
Q4 		$354M Buy
5,090,148
+641,322
+14% +$26.2M 0.16% 135
2025
Q3 		$125M Sell
4,448,826
-124,180
-3% -$2.47M 0.06% 241
2025
Q2 		$94.9M Buy
4,573,006
+217,812
+5% +$4.79M 0.05% 273
2025
Q1 		$86.1M Buy
4,355,194
+195,306
+5% +$4.78M 0.05% 284
2024
Q4 		$113M Buy
4,159,888
+203,010
+5% +$7.2M 0.06% 262
2024
Q3 		$174M Buy
3,956,878
+602,609
+18% +$23.3M 0.09% 203
2024
Q2 		$132M Buy
3,354,269
+1,277,569
+62% +$52.5M 0.07% 229
2024
Q1 		$89M Buy
2,076,700
+532,284
+34% +$22.4M 0.05% 282
2023
Q4 		$62.8M Sell
1,544,416
-546,907
-26% -$31.3M 0.04% 333
2023
Q3 		$97.5M Buy
2,091,323
+2,013,893
+2,601% +$64.9M 0.06% 248
2023
Q2 		$3.22M Sell
77,430
-268,991
-78% -$7.54M ﹤0.01% 1004
2023
Q1 		$3.29M Buy
+346,421
New +$8.14M ﹤0.01% 1021

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Janus Henderson Group's GPCR Position: Q1 2026 in Review

Janus Henderson Group increased its Structure Therapeutics (GPCR) stake by 5.2% in Q1 2026, buying an estimated $18.1M and bringing the position to 5,354,981 shares worth $258M. The position accounts for 0.12% of the portfolio, ranked #163.

Janus Henderson Group first reported a position in GPCR in Q1 2023 and has held it in 13 quarters since. The position peaked at $354M in Q4 2025. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

  • Janus Henderson Group held 5,354,981 shares of Structure Therapeutics worth $258M as of Q1 2026.
  • Janus Henderson Group bought 264,833 Structure Therapeutics shares in Q1 2026, an estimated $18.1M.
  • Structure Therapeutics made up 0.12% of Janus Henderson Group's portfolio in Q1 2026, its #163 holding.
  • Janus Henderson Group first reported a position in Structure Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • Janus Henderson Group's Structure Therapeutics position peaked at $354M in Q4 2025.
  • 196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.